Local News: Ashburn, VA 

 | 

Sign Up

 | 

Sign In

Keryx Biopharmaceuticals

Keryx Biopharmaceuticals News Editors

News Widget

Display the Keryx Biopharmaceuticals news headlines on your website.

Get the Topix Headlines Widget

Share & bookmark

RSS icon mobile icon

Keryx Biopharmaceuticals News

News on Keryx Biopharmaceuticals (Ticker: KERX) continually updated from thousands of sources around the net.

3 hrs ago | Theflyonthewall.com

On The Fly: Analyst Initiation Summary

Check below for free stories on KO;KERX;DPS;NBIX;SPN;PEP;CSG;CALD;SYRG;TEVA;VNTV;UBNT;MA;V;TSS;GPN;GDOT;MGI;FLT;HPY;WU;CORR the last two weeks.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Neurocrine Biosciences, Beverages, PepsiCo, World News, Germany, Stanley

7 hrs ago | AmericanBankingNews.com

JPMorgan Chase Initiates Coverage on Keryx Biopharmaceuticals

Keryx Biopharmaceuticals opened at 7.66 on Wednesday. Keryx Biopharmaceuticals has a 1-year low of $1.36 and a 1-year high of $9.98.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Fri Jun 07, 2013

BayStreet.ca

GSK, AZN, KERX, and RPTP Early Briefing and Review

Major drug manufacturers in the U.S., as well as globally, have been facing increasing competition from generic drug makers following the expiration of patents for several blockbuster drugs.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline

Tue Jun 04, 2013

Seeking Alpha

Solid Showing At WCN Conference For Keryx: Catalysts Still To Come

Keryx Biopharmaceuticals presented additional details from its pivotal Phase III study for Zerenex Monday at the World Congress of Nephrology meeting during a lunch presentation.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Nephrology, Dialysis, Health

Mon Jun 03, 2013

Insider Monkey

Hedge Funds Are Buying Keryx Biopharmaceuticals

In today's marketplace, there are many gauges investors can use to track publicly traded companies.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Thu May 30, 2013

Seeking Alpha

Keryx: Attractive In Front Of Catalyst-Rich Second Half

Shares of Keryx Biopharmaceuticals continue to trade within a tight range, but with several catalyzing events approaching, we believe the stock is ready to break out.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Nephrology

Fri May 24, 2013

Seeking Alpha

A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013

With a potential U.S. market for Chronic Kidney Disease and End Stage Renal Disease patients of almost $1bb, based on 5mm CKD patients above age 65, of whom ~50% are in stage 3-5, there is ample opportunity for a few under-appreciated stories focusing on this market to see real traction as we head into 2H/13. I've highlighted a few of the more ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, La Jolla Pharmaceutical, Healthcare Law, Law, Nephrology

Ashburn Jobs